When first-line systemic treatment for hepatocellular carcinoma fails, what comes next?

Katie Kelley, MD, is joined by fellow experts Anthony B. El-Khoueiry, MD, Laura W. Goff, MD, and Amit Signal, MD, for a discussion on the evolving hepatocellular carcinoma (HCC) treatment landscape, with a focus on second-line regimens. The team also reviews clinical guidelines and shares their thoughts on unmet needs in HCC.

Read the Supplement Here

Video 1: Analyzing the HCC Playing Field

The panelists review first- and second-line treatment options for HCC and discuss how they typically approach treating patients when first-line therapy fails.

Up Next

Analyzing the HCC Playing Field
Current HCC Guidelines
Looking Ahead

About the Panel

Dr. Kelley Photo

Katie Kelley, MD - Moderator

  • Associate Professor
  • University of California,
  • San Francisco, California
Dr. Hurvitz Photo

Laura W. Goff, MD

  • Associate Professor,
  • Vanderbilt University Medical Center,
  • Nashville, Tennessee
Dr. Brufsky Photo

Anthony B. El-Khoueiry, MD

  • Associate Professor,
  • Medical Director of Clinical Investigations Support Office
  • USC Norris Comprehensive Cancer Center,
  • Los Angeles, California
Dr. Veluswamy Photo

Amit Singal, MD, MS

  • Professor
  • University of Texas Southwestern Medical Center,
  • Dallas, Texas

Dr. Kelley has received grants from: Agios; AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Exelixis; EMD Serono; Merck; Novartis; QED; Taiho; Partner Therapeutics; and consulting fees from: GNE/Roche; Gilead; Exact Sciences

Dr. Goff discloses previous work with: Astellas; Pfizer; Onyx Pharmaceuticals; SunPharma; Eli Lilly and Company; Bristol-Myers Squibb; Agios-ArQule; H3 Biomedicine; Incyte; Leap Therapeutics; ASLAN; BeiGene; Basilea; Merck

Dr. El-Khoueiry has worked with: BMS; Bayer; Elsai; Merck; Exelixis; Agenus; Gilead; AstraZeneca; Roche; Genentech ; and received research grants from: Astex; AstraZeneca

Dr. Singal discloses work with Genentech; Bayer; Eisai; Exelixis; Bristol-Myers Squibb; AstraZeneca